H. pylori Eradication Treatment Causes Alterations in the Gut Microbiota and Blood Lipid Levels.

dc.contributor.authorMartín-Núñez, Gracia M
dc.contributor.authorCornejo-Pareja, Isabel
dc.contributor.authorRoca-Rodríguez, M Del Mar
dc.contributor.authorClemente-Postigo, Mercedes
dc.contributor.authorCardona, Fernando
dc.contributor.authorFernández-García, José C
dc.contributor.authorMoreno-Indias, Isabel
dc.contributor.authorTinahones, Francisco J
dc.date.accessioned2025-01-07T12:20:37Z
dc.date.available2025-01-07T12:20:37Z
dc.date.issued2020-08-11
dc.description.abstractBackground: The gut microbiome plays an important role in the lipid metabolism. Antibiotic treatment causes changes in the intestinal microbiota. Our objective was to explore the relationship between changes in the intestinal microbiota and the level of plasma high density lipoprotein cholesterol (HDL) and low density lipoprotein cholesterol (LDL). Methods: Prospective case-control study with Helicobacter pylori-positive patients undergoing eradication therapy with omeprazole, clarithromycin, and amoxicillin. Stool and blood samples were obtained from 20 controls (H. pylori negative) and 40 patients before and 2 months after antibiotic treatment. Gut microbiota was determined through 16S rRNA amplicon sequencing (Illumina MiSeq). Results: Eradication treatment for H. pylori increased the HDL levels, and caused changes in gut microbiota profiles. An unfavorable lipid profiles (high LDL and low HDL levels) was associated with a low microbial richness and an increase of the Bacteroidetes phylum. Prevotella copri, Lachonobacterium, and Delsufovibrio were positively associated with HDL while Rikenellaceae was negatively associated with HDL after completing antibiotic treatment. Conclusions:Helicobacter pylori eradication treatment could improve lipid metabolism in relation with an increase in the HDL. Changes in the abundance of specific bacteria, such as P. copri, Lachonobacterium, Delsufovibrio, and Rikenellaceae could be associated with change in the plasma HDL levels.
dc.identifier.doi10.3389/fmed.2020.00417
dc.identifier.issn2296-858X
dc.identifier.pmcPMC7431686
dc.identifier.pmid32850910
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7431686/pdf
dc.identifier.unpaywallURLhttps://www.frontiersin.org/articles/10.3389/fmed.2020.00417/pdf
dc.identifier.urihttps://hdl.handle.net/10668/24487
dc.journal.titleFrontiers in medicine
dc.journal.titleabbreviationFront Med (Lausanne)
dc.language.isoen
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.page.number417
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectH. pylori
dc.subjectHDL
dc.subjectLDL
dc.subjectantibiotic
dc.subjectgut microbiota
dc.titleH. pylori Eradication Treatment Causes Alterations in the Gut Microbiota and Blood Lipid Levels.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number7

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC7431686.pdf
Size:
486.77 KB
Format:
Adobe Portable Document Format